Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise

Executive Summary

Deals with TiGenix and Altos add to a growing gastrointestinal pipeline, as the Japanese pharma sees Entyvio and GI, not Velcade and cancer, as its primary growth-driver.

Advertisement

Related Content

Is Takeda's Consumer Unit 'Agile' Enough To Stretch Outside Japan?
Takeda Funds Celiac Asset As Prelude To Potential Acquisition
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register